Overview

TomoTherapy Incorporated is Reshaping Radiation Therapy™ with the TomoTherapy^® Hi·Art^® treatment system. By integrating CT imaging and helical intensity-modulated radiation therapy, our approach improves the effectiveness and efficiency of radiation treatment for the full range of cancer tumors.

Our company was founded on the premise that the best way to harness the power and precision of intensity-modulated radiation therapy (IMRT) is with integrated imaging technology that can guarantee accuracy at every treatment fraction.

Today, cancer centers and solution providers alike recognize the need for image guidance. 17 years ago, a team of researchers at the University of Wisconsin-Madison (led by “Rock” Mackie and Paul Reckwerdt) set out to address that need.

By mounting the linear accelerator (linac) of the Hi·Art treatment system on a ring gantry, the UW group moved beyond legacy design limitations with their first step. In so doing, they opened the door for 360° fan-beam delivery of IMRT and fully-integrated, megavoltage CT imaging. This advance gave clinicians the ability to better focus radiation beams, and the flexibility to adapt daily treatment based on shifting targets and changing patient anatomy. It also created entirely new options for treating the most complex cases.

Since then, a lot has transpired, including the 1997 establishment of TomoTherapy Incorporated. Now 10 years and 150+ Hi·Art installations in 16+ countries later, we remain on the same path that began with a simple step in the right direction.

A publicly-traded company (NASDAQ:TOMO), TomoTherapy Inc. is based in the U.S. with European offices in Belgium and distribution throughout the world. The company owns multiple issued U.S. patents and has a number of patent applications pending, both in the U.S. and worldwide. The company also holds an exclusive license on more than 100 issued patents and pending applications globally.